Cantitate/Preț
Produs
Total produse
Vezi coșul
Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications de Gail Lewis Phillips

Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications: Cancer Drug Discovery and Development

Editat de Gail Lewis Phillips
en Limba Engleză Hardback – 12 dec 2012
This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 106765 lei  6-8 săpt.
  Springer – 28 ian 2015 106765 lei  6-8 săpt.
Hardback (1) 107494 lei  6-8 săpt.
  Springer – 12 dec 2012 107494 lei  6-8 săpt.

Din seria Cancer Drug Discovery and Development

  • 5% CNS Cancer: Models, Markers, Prognostic Factors, Targets, and Therapeutic Approaches
    Preț: 143261 lei
  • 5% Developments in T Cell Based Cancer Immunotherapies
    Preț: 107654 lei
  • 5% mTOR Pathway and mTOR Inhibitors in Cancer Therapy
    Preț: 137506 lei
  • 5% Antiangiogenic Agents in Cancer Therapy
    Preț: 137017 lei
  • 5% Tumor Models in Cancer Research
    Preț: 141057 lei
  • 5% Telomeres and Telomerase in Cancer
    Preț: 131671 lei
  • 5% Gene Therapy for Cancer
    Preț: 139816 lei
  • 5% Proteasome Inhibitors in Cancer Therapy
    Preț: 108166 lei
  • 5% Oncogene-Directed Therapies
    Preț: 109393 lei
  • 24% Protein Tyrosine Kinases: From Inhibitors to Useful Drugs
    Preț: 103758 lei
  • 5% Cancer Chemoprevention: Volume 2: Strategies for Cancer Chemoprevention
    Preț: 142423 lei
  • 5% Apoptosis, Senescence and Cancer
    Preț: 135076 lei
  • 5% Bioinformatics in Cancer and Cancer Therapy
    Preț: 137682 lei
  • 5% Bone Metastasis
    Preț: 108151 lei
  • 5% Nitric Oxide (NO) and Cancer: Prognosis, Prevention, and Therapy
    Preț: 138752 lei
  • 5% Tumor Suppressor Genes in Human Cancer
    Preț: 138873 lei
  • 5% Platinum-Based Drugs in Cancer Therapy
    Preț: 75971 lei
  • 5% Regional Cancer Therapy
    Preț: 139727 lei
  • 5% Checkpoint Controls and Targets in Cancer Therapy
    Preț: 107844 lei
  • 5% Antifolate Drugs in Cancer Therapy
    Preț: 139319 lei
  • 5% Transforming Growth Factor-Beta in Cancer Therapy, Volume II: Cancer Treatment and Therapy
    Preț: 136580 lei
  • 5% Transforming Growth Factor-Beta in Cancer Therapy, Volume I: Basic and Clinical Biology
    Preț: 141911 lei
  • 5% Farnesyltransferase Inhibitors in Cancer Therapy
    Preț: 107508 lei
  • 5% Supportive Care in Cancer Therapy
    Preț: 98217 lei
  • 5% Nucleic Acid Therapeutics in Cancer
    Preț: 70697 lei
  • 5% Stem Cells and Cancer
    Preț: 133174 lei
  • 5% EGFR Signaling Networks in Cancer Therapy
    Preț: 129738 lei
  • 5% Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics
    Preț: 109233 lei
  • 5% Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy
    Preț: 139193 lei
  • 5% Hormone Therapy in Breast and Prostate Cancer
    Preț: 107900 lei
  • 5% Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications
    Preț: 131774 lei
  • 5% The Oncogenomics Handbook
    Preț: 142282 lei
  • 5% Macromolecular Anticancer Therapeutics
    Preț: 188387 lei
  • 5% Histone Deacetylases: Transcriptional Regulation and Other Cellular Functions
    Preț: 137773 lei
  • 5% Cancer Drug Resistance
    Preț: 139761 lei
  • 5% Matrix Metalloproteinase Inhibitors in Cancer Therapy
    Preț: 106870 lei
  • 5% Fluoropyrimidines in Cancer Therapy
    Preț: 107810 lei
  • 5% In Vivo Imaging of Cancer Therapy
    Preț: 99056 lei
  • 5% The Tumor Microenvironment
    Preț: 140168 lei
  • 5% Camptothecins in Cancer Therapy
    Preț: 138787 lei
  • 5% Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins
    Preț: 76502 lei
  • 5% Cancer Proteomics: From Bench to Bedside
    Preț: 131170 lei
  • 5% Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response
    Preț: 133174 lei
  • 5% COX-2 Blockade in Cancer Prevention and Therapy
    Preț: 108116 lei
  • 5% Cytokines in the Genesis and Treatment of Cancer
    Preț: 139938 lei

Preț: 107494 lei

Preț vechi: 113151 lei
-5% Nou

Puncte Express: 1612
Preț estimativ în valută:
20572€ • 21641$ • 17165£

Carte tipărită la comandă

Livrare economică 09-23 ianuarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781461454557
ISBN-10: 1461454557
Pagini: 388
Ilustrații: X, 378 p.
Dimensiuni: 155 x 235 x 26 mm
Greutate: 0.73 kg
Ediția:2013
Editura: Springer
Colecția Humana
Seria Cancer Drug Discovery and Development

Locul publicării:New York, NY, United States

Public țintă

Research

Cuprins

Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins.- Antibody-Drug Conjugate Development.- Components of ADC Development: Assay Methodologies and Challenges.- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates.- Predictive Biomarkers for Antibody-Drug Conjugates.- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates.- Linker Technology and Impact of Linker Design on ADC Properties.- Antibody-drug conjugates for the treatment of B-cell malignancies.- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies.- Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies.- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer.- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE).- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer.- EphA2 Immunoconjugate.- Anti-PSMA Antibody-Drug Conjugates.- Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine.- Studies on the Metabolism of Antibody-Drug Conjugates.- Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu.- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors.- Index.

Textul de pe ultima copertă

The concept of delivering ‘magic bullets’ to treat diseases was first proposed by Paul Erlich in the early 1900’s.  The realization of this concept for the treatment of cancer occurred in the late 1990’s with the approval of monoclonal antibody therapies.  The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. 

ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics.  More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use.  This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologicand solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.

Caracteristici

Features up-to-date research Provides an exhaustive review of anti-body drug conjugate and immunotoxin targets Explores new technologies for site-specific conjugation